MICHAEL JOSEPH LUZZIO,JULIEN PAPILLON,MICHAEL SCOTT VISSER
申请号：
PT15750138
公开号：
PT3177608T
申请日:
2015.08.05
申请国别(地区):
PT
年份:
2019
代理人:
摘要：
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
